PhysIQ, a Naperville, Illinois-based provider of proprietary predictive analytics for human physiology, raised $4.6m in Series A funding.
The round was led by LionBird.
The company intends to use the funds to accelerate corporate growth via additional clinical studies and regulatory filings. It plans to submit a 510(k) to the FDA later this year.
Led by Gary Conkright, CEO, PhysIQ provides proprietary predictive analytic technology designed to detect subtle changes in vital signs and other health indicators to allow both clinicians to manage patients who are suffering from chronic illness, as well as consumers interested in tracking their own health and fitness levels. It analyzes numerous data streams originating from any sensor or wearable device to gather key data about a patient’s physiology, including heart rate, blood pressure, oxygenation of the blood, respiration rate and many other biological signals.
The platform constructs a personalized baseline norm for each person monitored and can be embedded into patient monitoring devices from other manufacturers who are seeking to design “smarter” products.